Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment.

No abstract is available for this paper.

• Publication year

  2000

• Venue

  Blood

• Publication date

  2000-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1182/BLOOD.V96.5.1816PMID 10961881
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications.

  1999cited by this paper
• Decentralised anticoagulant care.

  1998cited by this paper
• Guidelines on oral anticoagulation: third edition

  1998cited by this paper
• Guidelines on oral anticoagulation: third edition.

  1998cited by this paper
• Decentralised anticoagulant care.

  1998cited by this paper
• Analysis of risk factors for over‐anticoagulation in patients receiving long‐term warfarin

  1998cited by this paper
• Should patients starting anticoagulant therapy be screened for missense mutations at Ala-10 in the factor IX propeptide?

  1997cited by this paper
• Reliability of delayed INR determination: implications for decentralized anticoagulant care with off‐site blood sampling

  1997cited by this paper
• Missense mutations at ALA‐10 in the factor IX propeptide: an insignificant variant in normal life but a decisive cause of bleeding during oral anticoagulant therapy

  1997cited by this paper
• The R144C change in the CYP2C9*2 allele alters interaction of the cytochrome P450 with NADPH:cytochrome P450 oxidoreductase.

  1997cited by this paper
• Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy.

  1996cited by this paper
• Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT)

  1996cited by this paper
• A mutation in the propeptide of Factor IX leads to warfarin sensitivity by a novel mechanism.

  1996cited by this paper
• Allelic variants of human cytochrome P450 2C9: baculovirus-mediated expression, purification, structural characterization, substrate stereoselectivity, and prochiral selectivity of the wild-type and I359L mutant forms.

  1996cited by this paper
• Genetic analysis of the human cytochrome P450 CYP2C9 locus.

  1996cited by this paper
• Optimal oral anticoagulant therapy in patients with mechanical heart valves.

  1995cited by this paper
• Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9.

  1994cited by this paper
• Bleeding complications in oral anticoagulant therapy. An analysis of risk factors.

  1993cited by this paper
• A Method to Determine the Optimal Intensity of Oral Anticoagulant Therapy

  1993cited by this paper
• Bleeding complications in oral anticoagulant therapy : an analysis of risk factors

  1993cited by this paper
• Bleeding Complications in Oral Anticoagulant Therapy

  1993cited by this paper
• Effect of laboratory variation in the prothrombin-time ratio on the results of oral anticoagulant therapy.

  1993cited by this paper
• Statistics with confidence: Confidence intervals and statistical guidelines .

  1990cited by this paper
• Computer assisted management of warfarin treatment.

  1984cited by this paper

• Clinical Application of Pharmacogenomics in Stroke Management: Current Evidence and Future Directions

  2026cites this paper
• A Digital Twin of the Angiotensin II Receptor Blocker Losartan: Physiologically Based Modeling of Blood Pressure Regulation.

  2026cites this paper
• Anticoagulation Therapies and microRNAs in Heart Failure

  2025cites this paper
• Being precise with anticoagulation to reduce adverse drug reactions: are we there yet?

  2024cites this paper
• Cost-Effectiveness Analysis of Pharmacogenomics-Guided Versus Standard Dosing of Warfarin in Patients with Mechanical Prosthetic Heart Valve

  2024cites this paper
• Association between CYP2C9 and VKORC1 genetic polymorphisms and efficacy and safety of warfarin in Chinese patients

  2024cites this paper
• Antivitamines K : pharmacologie et pharmacogénétique

  2024cites this paper
• Pharmacogenetic Biomarkers and Personalized Medicine: Upcoming Concept in Pharmacotherapy

  2022cites this paper
• Frequency of CYP2C9 Promoter Variable Number Tandem Repeat Polymorphism in a Spanish Population: Linkage Disequilibrium with CYP2C9*3 Allele

  2022cites this paper
• Warfarin Dosing in Patients With CYP2C9*5 Variant Alleles

  2022cites this paper
• Illustrative and historic cases of phenoconversion.

  2021cites this paper
• Effect of gene polymorphism on bleeding complications in Chinese Han patients taking warfarin

  2021cites this paper
• Verification of pharmacogenomics-based algorithms to predict warfarin maintenance dose using registered data of Japanese patients

  2019cites this paper
• The influence of age, vitamin K and genetics on anticoagulation outcomes in adults and children

  2019cites this paper
• Interplay between genetics and epigenetics in modulating the risk of venous thromboembolism: A new challenge for personalized therapy.

  2019cites this paper
• Oral Anticoagulant Prescription Trends, Profile Use, and Determinants of Adherence in Patients with Atrial Fibrillation

  2019cites this paper
• Genetic risk assessment towards warfarin application: Saudi Arabia study with a potential to predict and prevent side effects

  2019cites this paper
• Pharmacogenomics in Papua New Guineans: unique profiles and implications for enhancing drug efficacy while improving drug safety

  2018cites this paper
• Pharmacogenetics of Adverse Drug Reactions.

  2018cites this paper
• Impact of CYP2C9 and VKORC1 Polymorphisms on Warfarin Sensitivity and Responsiveness in Jordanian Cardiovascular Patients during the Initiation Therapy

  2018cites this paper
• Antagonistes de la vitamine K : utilisation pratique

  2018cites this paper
• РАСПРОСТРАНЁННОСТЬ ПОЛИМОРФИЗМОВ ГЕНОВ ЦИТОХРОМОВ Р450 – МЕТАБОЛИЗАТОРОВ ВАРФАРИНА – В ВОСТОЧНОЙ СИБИРИ

  2018cites this paper
• Dedicated warfarin care programme results in superior warfarin control in Queensland, Australia

  2018cites this paper
• FREQUENCIES OF POLYMORPHISMS IN THE CYTOCHROME’S P450 GENES OF WARFARIN TRANSFORMATION IN A EUROPEAN POPULATION OF EASTERN SIBERIA

  2018cites this paper
• Genetics of warfarin resistance Two enzymes essential for the vitamin K cycle

  2017cites this paper
• Adverse Drug Events

  2017cites this paper
• Study of environmental and genetic factors determining warfarin toxicity

  2017cites this paper
• Thrombosis and haemostasis : Biological considerations and pharmacological issues

  2017cites this paper
• The allele frequency of CYP2C9 and VKORC1 in the Southern Khorasan population

  2017cites this paper
• Effect of VKORC1 and CYP2C9 polymorphisms on warfarin dose requirement in Bangladeshi population.

  2017cites this paper
• Pharmacogenomics of CYP2C9: Functional and Clinical Considerations†

  2017cites this paper
• Risk of development of hemorrhagic complications due to warfarin therapy

  2017cites this paper
• Potential Social, Ethical, and Legal Issues Raised by the Development of Pharmacogenetics

  2016cites this paper
• [Interaction between amoxicillin clavulanic acid and fluindione: Two case reports].

  2016cites this paper
• Concepts in Pharmacogenomics and Personalized Medicine

  2016cites this paper
• CYP4F2 (rs2108622) Gene Polymorphism Association with Age-Related Macular Degeneration

  2016cites this paper
• Anticoagulothérapie à la warfarine : influence de l’apport alimentaire de vitamine K

  2016cites this paper
• Clinical Predictors Associated With Warfarin Sensitivity

  2016cites this paper
• Issues of Pharmacogenomics in Monitoring Warfarin Therapy

  2016cites this paper
• Significance of Pharmacogenetics and Pharmacogenomics Research in Current Medical Practice.

  2016cites this paper
• Genetic determinants of response and adverse effects following vitamin K antagonist oral anticoagulants

  2016cites this paper
• Analysis of CYP2C9 polymorphisms (*2 and *3) in warfarin therapy patients in Pakistan. Association of CYP2C9 polymorphisms (*2 and*3) with warfarin dose, age, PT and INR

  2015cites this paper
• Implementation of a Computerized Decision Support System for Warfarin Dosing in Hemodialysis Patients: A Study of Effectiveness and Safety

  2015cites this paper
• Étude pharmacogénomique de la warfarine et de l'activité physique

  2015cites this paper
• Impact of regular physical activity on weekly warfarin dose requirement

  2015cites this paper
• Pharmacogenetic-guided algorithms to estimate personalized dose or individual responses to anti-thrombotic drugs

  2015cites this paper
• Drug Information Rounds

  2015cites this paper
• Pharmacogenetics aspects of oral anticoagulants therapy

  2015cites this paper
• Journal of Pharmaceutical and Biological Sciences

  2015cites this paper
• Pharmacogenetics of drug-metabolizing enzymes in US Hispanics

  2015cites this paper
• Allele Frequency Distributions of the Drug Metabolizer Genes CYP 2 C 9 * 2 , CYP 2 C 9 * 3 , and CYP 2 C 19 * 17 in the Buginese Population of Indonesia

  2015cites this paper
• Drug-Drug Interactions: Where Do We Go From

  2015cites this paper
• Genomic architecture of pharmacological efficacy and adverse events.

  2014cites this paper
• [Cardiovascular pharmacogenomics].

  2014cites this paper
• New oral anticoagulants and the cancer patient.

  2014cites this paper
• Investigating the Role of Plasma Glucose Concentration as a Phenotypic Marker for CYP2C9 Genetic Variants, in the Diabetic Population of Gujarat

  2014cites this paper
• Drug Response Heterogeneity and the Genetic Variability of Cytochrome P450–Metabolizing Enzymes

  2014cites this paper
• The Pharmacogenomics of Cytochrome P450s: From Molecular to Clinical Application

  2014influential citation
• Pharmacogenomics of Warfarin

  2014cites this paper
• Association of gene polymorphisms with the risk of warfarin bleeding complications at therapeutic INR in patients with mechanical cardiac valves

  2014cites this paper
• Optimal INR level in Thai atrial fibrillation patients who were receiving warfarin for stroke prevention in Thailand.

  2014cites this paper
• A study of correlation between CYP2C9 gene polymorphism and Warfarin maintenance dose in anticoagulant therapy among Han people in Yunnan of China

  2014cites this paper
• Pharmacogenetic biomarkers for predicting drug response

  2014cites this paper
• Case report: dose adjustment of warfarin using genetic information and plasma concentration monitoring

  2014cites this paper
• Genetic epidemiology of pharmacogenetic variations in CYP2C9, CYP4F2 and VKORC1 genes associated with warfarin dosage in the Indian population.

  2014cites this paper
• Drug Interactions, Pharmacogenomics and Cardiovascular Complication

  2013cites this paper
• Genetic Bleeding Risk Score (GBRS) for Patients on Oral Anticoagulant Therapy

  2013cites this paper
• Optimal dosing of warfarin and other coumarin anticoagulants: the role of genetic polymorphisms

  2013cites this paper
• Influence of CYP2C9 and VKORC1 genotypes on the risk of hemorrhagic complications in warfarin-treated patients: a systematic review and meta-analysis.

  2013cites this paper
• Hemostasis and Thrombosis

  2013cites this paper
• Comparative genetics of warfarin resistance

  2013cites this paper
• Applications of CYP450 Testing in the Clinical Setting

  2013cites this paper
• Role of CYP2C9, VKORC1 and Calumenin Genotypes in Monitoring Warfarin Therapy: An Egyptian Study

  2013cites this paper
• interindividual variability in the dose-anticoagulant effect of warfarin A polymorphism in the VKORC1 gene is associated with an

  2013cites this paper
• Overview of Warfarin Treatment and Answers to Questions

  2013influential citation
• Genetics of Population Differences in Drug Response

  2013cites this paper
• Pharmacogenetic testing: current evidence of clinical utility

  2013cites this paper
• Warfarin pharmacogenomics in children

  2013cites this paper
• Evaluation of the Impact of UGT Polymorphism on the Pharmacokinetics and Pharmacodynamics of the Novel PPAR Agonist Sipoglitazar

  2013cites this paper
• Genetic and Environmental Factors

  2013cites this paper
• Vom Heparin zum Apixaban: Was bringen die „neuen Antikoagulanzien“?

  2013cites this paper
• Sex differences in the effective warfarin dosage in Han and aboriginal Taiwanese patients with the VKORC1-1639AA genotype

  2013cites this paper
• When blood is thinner than water.

  2013cites this paper
• Impact of genetic and clinical factors on dose requirements and quality of anticoagulation therapy in Polish patients receiving acenocoumarol: dosing calculation algorithm

  2013cites this paper
• Identification of the factors influencing anticoagulation response to warfarin in children

  2012cites this paper
• Interethnic and Intraethnic Variability of CYP2C8 and CYP2C9 Polymorphisms in Healthy Individuals

  2012cites this paper
• Handbook of Drug Interactions: A Clinical and Forensic Guide, 2nd Edition

  2012cites this paper
• Management of atrial fibrillation: direct factor IIa and Xa inhibitors or "warfarin shotgun"?

  2012cites this paper
• CYP2C9 on sensitivity to acenocoumarol Differential effects of 2C9*3 and 2C9*2 variants of cytochrome P-450

  2012cites this paper
• Perceived stress predicts the stability of vitamin K-antagonist treatment of anticoagulant clinic patients

  2012cites this paper
• related to the acenocoumarol dose requirement in a Spanish population are not CYP2C9 Leu208Val and Ile181Leu variants of cytochrome P450

  2012cites this paper
• Anticoagulation par antivitamines K: analyse des interactions médicamenteuses et des polymorphismes génétiques à l'origine de la variabilité de la réponse et des risques liés à l'acénocoumarol

  2012cites this paper
• Influence of CYP2C9 and VKORC1 on Patient Response to Warfarin: A Systematic Review and Meta-Analysis

  2012influential citation
• The Development, Validation and Implementation of a Broad-Based ADME Genotyping Assay into Research and Clinical Trials

  2012cites this paper
• Influence of warfarin dose-associated genotypes on the risk of hemorrhagic complications in Chinese patients on warfarin

  2012cites this paper
• Interethnic Diversity of CYP2C9 Alleles on Warfarin Pharmacogenetics in Healthy Sindhi and Baluchi Population Samples: Correlation to Global Allelic Frequencies

  2012cites this paper
• Prevalence of VKORC1 and CYP2C9 gene polymorphisms in Indian population and its effect on warfarin response.

  2012cites this paper
• Effect of Genetic Variants, Especially CYP2C9 and VKORC1, on the Pharmacology of Warfarin

  2012cites this paper
• Allele and Genotype Frequencies of CYP2C9 Within an Iranian Population (Mazandaran)

  2012influential citation
• Novel anticoagulants in atrial fibrillation stroke prevention

  2012cites this paper